/Companies

Lutris Pharma

5 known investors

Find your way into Lutris Pharma

Sign up to see every warm intro you have to Lutris Pharma

  • Paths you didn't know you had: your email and LinkedIn already hold routes to the Lutris Pharma team. We find them for you
  • 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
  • Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Lutris Pharma develops targeted skin protection treatments for cancer patients, combining clinicians and scientists with oncology expertise. The company focuses on pharmaceutical development in the oncology and dermatology space.

Founders & leadership

AR
Antoni Ribas, M.D., Ph.D.Founder and Chairman of the Board
SRSumant Ramachandra
Sumant RamachandraChief Executive Officer and Board DirectorSumant Ramachandra is CEO and Board Director of Lutris Pharma, a company developing targeted skin protection treatments for cancer patients. He holds an MD and PhD from Rutgers University, completed medical training at Massachusetts General Hospital under Harvard Medical School, and earned an MBA from Wharton Business School, with 25+ years of experience in biotechnology, pharmaceuticals, and medical technology.
JB
Jonathan BenjaminClinical Development Lead
OG
Ofir GoldbergerOperations and Strategy Lead

Investors · 5

In the news

Frequently asked questions

What does Lutris Pharma do?
Lutris Pharma develops targeted skin protection treatments for cancer patients, combining clinicians and scientists with oncology expertise. The company focuses on pharmaceutical development in the oncology and dermatology space.
Who founded Lutris Pharma?
Lutris Pharma was founded by Antoni Ribas, M.D., Ph.D..
Who are Lutris Pharma's investors?
Lutris Pharma's investors include aMoon, Peregrine Ventures, Pontifax Venture Capital, Arkin Capital, Columbus Venture Partners.